 |
|
New blood test for Down syndrome
October 07, 2008Howard Hughes Medical Institute researchers have developed a new prenatal blood test that accurately detected Down syndrome and two other serious chromosomal defects in a small study of 18 pregnant women. If confirmed in larger trials, they say, the test would offer a safer and faster alternative to invasive prenatal tests such as amniocentesis that pose a small risk of miscarriage.
Researchers have long known that a pregnant woman's blood contains small amounts of DNA from the fetus. Howard Hughes Medical Institute researcher Stephen R. Quake and colleagues at Stanford University devised an ingenious way to the scan fetal DNA present in the mother's blood to determine whether the fetus' cells contain extra chromosomes associated with several types of severe birth detects.
The test developed by Quake's team was more accurate than techniques used in previous efforts to diagnose aneuploidy by analyzing fetal DNA. Aneuploidy occurs when there are either too many or too few chromosomes in cells. Down syndrome, for example, is caused by a trisomy -- three copies instead of two -- of chromosome 21.
"We believe this is the first demonstration of a universal, noninvasive test for Down and other aneuploidies," said Quake, senior author of the research article, which was published online in the early edition of the Proceedings of the National Academy of Sciences (PNAS) on October 6, 2008. "We need a larger clinical study to understand a bit more about the best way to implement it, but I am highly optimistic it will be used as a diagnostic test in short order."
Amniocentesis and chorionic villus sampling (CVS), which are currently considered the "gold standard" in prenatal testing, involve sampling cells in amniotic fluid. Those cells are obtained by inserting a needle into the mother's uterus. The procedure carries up to a one percent risk of inducing a miscarriage. For that reason, routine use of these invasive diagnostic tests has largely been limited to women age 35 and older, where the age-related risk of fetal aneuploidy outweighs the risk of miscarriage. As a result, more infants with chromosomal defects are now being born to younger women. Researchers have been working for years to devise noninvasive screening tests that would be safe for that group of women.
In addition, it takes two or three weeks following the amniocentesis or CVS procedures to culture the cells and study the chromosomes. That amount of time can seem like an eternity for anxious parents waiting for the test results, Quake said.
With the new test, scientists only need to draw a small amount of blood from the woman. The blood is analyzed and the results are available within a couple of days, said Quake, who is a bioengineer at Stanford.
Quake's interest in developing new technology to diagnose aneuploidies was sparked when he read a research article published in the journal Science in 2005. That article discussed new methods of noninvasive prenatal testing that relied on measurements of DNA in fetal cells present in the mother's blood. The report said that the low prevalence of fetal cells - only about one in one million maternal cells - made it difficult to isolate enough fetal cells to test for chromosomal abnormalities.
At the time, some researchers were trying to isolate fetal "cell-free DNA" from the mother's blood. Cell-free DNA is fragmented double-stranded DNA that is in the debris of dying fetal cells. Isolating this DNA was a good idea, Quake said, but recovering the vanishingly small amount of fetal cell-free DNA remained a challenge.
After reading the Science article, Quake thought to himself, 'A lot of my work is about counting molecules; this is one problem I know how to do.' He had a brainstorm: Where other researchers were developing various ways of amplify the fetal DNA signal to distinguish it from maternal DNA, Quake proposed a bold shortcut - skipping that step entirely. After all, he observed, the point of screening was to spot extra chromosomes in the woman's blood sample. Whether the DNA being scanned was from the fetus or from the mother didn't matter. The objective, therefore, was simply to measure the amount of DNA in fragments mapped to the different chromosomes.
Conveniently, the cell-free DNA floating in the mother's blood circulation normally exists in short pieces, averaging 169 nucleotides in length. Quake proposed a "shotgun sequencing" strategy where he would use the very latest high-throughput gene sequencing technology and equally powerful computers to identify millions of unique sequence "tags" in the fetal DNA. Each of these tags was a 25 base-pair fragment of DNA. After the tags were identified, Quake's group could then map them to specific locations on the 23 pairs of chromosomes. By using this strategy, the researchers believed they could detect higher-than normal amounts of DNA belonging to the three chromosomes involved in the most common aneuploidies -- chromosomes 21, 18, and 13.
In the experiments reported in PNAS, Quake and his colleagues, including first author H. Christina Fan, a graduate student in bioengineering at Stanford, used their new technique to analyze DNA in blood samples from 18 pregnant women who were undergoing invasive prenatal testing (and one man, for reference).
When the amounts of DNA corresponding to each chromosome were plotted on a graph, significant, above-normal peaks appeared when a chromosome was present in three copies instead of two. These signals enabled the scientists to correctly identify the 12 women who carried aneuploid fetuses and the six whose pregnancies were normal. Their results matched those of amniocentesis or CVS test that were done on the women.
Quake said the shotgun-sequencing system is not only safer than invasive techniques but can also make a determination at an earlier gestational age, around 12 weeks.
The earlier the couple knows the status of the pregnancy, Quake observed, the better they will be prepared for whatever decision they choose to make on the basis of the information.
Quake's group is now planning a follow-up study to evaluate the test in a larger group of patients. He estimates that the cost of the test during the next phase will be about $300, with DNA sequencing accounting for the majority of the overall cost.
Howard Hughes Medical Institute
"We believe this is the first demonstration of a universal, noninvasive test for Down and other aneuploidies," said Quake, senior author of the research article, which was published online in the early edition of the Proceedings of the National Academy of Sciences (PNAS) on October 6, 2008. "We need a larger clinical study to understand a bit more about the best way to implement it, but I am highly optimistic it will be used as a diagnostic test in short order."
Amniocentesis and chorionic villus sampling (CVS), which are currently considered the "gold standard" in prenatal testing, involve sampling cells in amniotic fluid. Those cells are obtained by inserting a needle into the mother's uterus. The procedure carries up to a one percent risk of inducing a miscarriage. For that reason, routine use of these invasive diagnostic tests has largely been limited to women age 35 and older, where the age-related risk of fetal aneuploidy outweighs the risk of miscarriage. As a result, more infants with chromosomal defects are now being born to younger women. Researchers have been working for years to devise noninvasive screening tests that would be safe for that group of women.
In addition, it takes two or three weeks following the amniocentesis or CVS procedures to culture the cells and study the chromosomes. That amount of time can seem like an eternity for anxious parents waiting for the test results, Quake said.
With the new test, scientists only need to draw a small amount of blood from the woman. The blood is analyzed and the results are available within a couple of days, said Quake, who is a bioengineer at Stanford.
Quake's interest in developing new technology to diagnose aneuploidies was sparked when he read a research article published in the journal Science in 2005. That article discussed new methods of noninvasive prenatal testing that relied on measurements of DNA in fetal cells present in the mother's blood. The report said that the low prevalence of fetal cells - only about one in one million maternal cells - made it difficult to isolate enough fetal cells to test for chromosomal abnormalities.
At the time, some researchers were trying to isolate fetal "cell-free DNA" from the mother's blood. Cell-free DNA is fragmented double-stranded DNA that is in the debris of dying fetal cells. Isolating this DNA was a good idea, Quake said, but recovering the vanishingly small amount of fetal cell-free DNA remained a challenge.
After reading the Science article, Quake thought to himself, 'A lot of my work is about counting molecules; this is one problem I know how to do.' He had a brainstorm: Where other researchers were developing various ways of amplify the fetal DNA signal to distinguish it from maternal DNA, Quake proposed a bold shortcut - skipping that step entirely. After all, he observed, the point of screening was to spot extra chromosomes in the woman's blood sample. Whether the DNA being scanned was from the fetus or from the mother didn't matter. The objective, therefore, was simply to measure the amount of DNA in fragments mapped to the different chromosomes.
Conveniently, the cell-free DNA floating in the mother's blood circulation normally exists in short pieces, averaging 169 nucleotides in length. Quake proposed a "shotgun sequencing" strategy where he would use the very latest high-throughput gene sequencing technology and equally powerful computers to identify millions of unique sequence "tags" in the fetal DNA. Each of these tags was a 25 base-pair fragment of DNA. After the tags were identified, Quake's group could then map them to specific locations on the 23 pairs of chromosomes. By using this strategy, the researchers believed they could detect higher-than normal amounts of DNA belonging to the three chromosomes involved in the most common aneuploidies -- chromosomes 21, 18, and 13.
In the experiments reported in PNAS, Quake and his colleagues, including first author H. Christina Fan, a graduate student in bioengineering at Stanford, used their new technique to analyze DNA in blood samples from 18 pregnant women who were undergoing invasive prenatal testing (and one man, for reference).
When the amounts of DNA corresponding to each chromosome were plotted on a graph, significant, above-normal peaks appeared when a chromosome was present in three copies instead of two. These signals enabled the scientists to correctly identify the 12 women who carried aneuploid fetuses and the six whose pregnancies were normal. Their results matched those of amniocentesis or CVS test that were done on the women.
Quake said the shotgun-sequencing system is not only safer than invasive techniques but can also make a determination at an earlier gestational age, around 12 weeks.
The earlier the couple knows the status of the pregnancy, Quake observed, the better they will be prepared for whatever decision they choose to make on the basis of the information.
Quake's group is now planning a follow-up study to evaluate the test in a larger group of patients. He estimates that the cost of the test during the next phase will be about $300, with DNA sequencing accounting for the majority of the overall cost.
Howard Hughes Medical Institute
Chromosomes Current Events and Chromosomes News RSSPlant polymerases IV and V are special forms of Polymerase II
It's a little like finding out that Superman is actually Clark Kent. A team of biologists at Washington University in St. Louis has discovered that two vital cellular components, nuclear RNA Polymerases IV and V (Pol IV and V), found only in plants, are actually specialized forms of RNA Polymerase II, an essential enzyme of all eukaryotic organisms, including humans.
Team finds breast cancer gene linked to disease spread
A team of researchers at Princeton University and The Cancer Institute of New Jersey has identified a long-sought gene that is fatefully switched on in 30 to 40 percent of all breast cancer patients, spreading the disease, resisting traditional chemotherapies and eventually leading to death.
New genetic markers for ulcerative colitis identified, researchers report in Nature Genetics
An international team led by University of Pittsburgh School of Medicine researchers has identified genetic markers associated with risk for ulcerative colitis.
How chromosomes meet in the dark -- Switch that turns on X chromosome matchmaking
A research group lead by scientists at the University of Warwick has discovered the trigger that pulls together X chromosomes in female cells at a crucial stage of embryo development. Their discovery could also provide new insights into how other similar chromosomes spontaneously recognize each other and are bound together at key parts of analogous cell processes.
UT Southwestern researchers identify gene linked to inherited form of fatal lung disease
Researchers at UT Southwestern Medical Center have determined that a mutation in a gene known for its role in defending the lungs against invading pathogens is responsible for some inherited cases of a lethal lung disease affecting older adults. The same mutation may also be associated with lung cancer, the researchers said.
USC researchers identify key mechanism that occurs at the inception point of many human lymphomas
Researchers at the Keck School of Medicine of the University of Southern California (USC) have explained how certain key mutations occur in human lymphomas-a process that has, until now, remained a mystery.
Stowers Institute's Workman Lab discovers novel histone demethylase protein complex
The Stowers Institute's Workman Lab has discovered a novel histone demethylase protein complex characterized in work published today in Molecular Cell.
Researchers solve piece of large-scale gene silencing mystery
A team led by Craig Pikaard, Ph.D., Washington University in St. Louis professor of biology in Arts & Sciences, has made a breakthrough in understanding the phenomenon of nucleolar dominance, the silencing of an entire parental set of ribosomal RNA genes in a hybrid plant or animal.
St. Jude identifies genomic causes of a certain type of leukemia relapse
Scientists at St. Jude Children's Research Hospital have identified distinctive genetic changes in the cancer cells of children with acute lymphoblastic leukemia (ALL) that cause relapse. The finding offers a pathway to designing treatments for ALL relapse in children and, ultimately, in adults.
Scripps Research Scientists Shed Light on How DNA Is Unwound So That Its Code Can Be Read
Researchers at The Scripps Research Institute have figured out how a macromolecular machine is able to unwind the long and twisted tangles of DNA within a cell's nucleus so that genetic information can be "read" and used to direct the synthesis of proteins, which have many specific functions in the body.
More Chromosomes Current Events and Chromosomes News Articles
 | Chromosome 6 by Robin Cook In his most prophetic novel, Robin Cook challenges the ethics of genetic manipulation and cloning. "Shocking and thought-provoking...Cook's best to date." (ssociated... |
 | The Calcutta Chromosome: A Novel of Fevers, Delirium & Discovery by Amitav Ghosh From Victorian lndia to near-future New York, The Calcutta Chromosome takes readers on a wondrous journey through time as a computer programmer trapped in a mind-numbing job hits upon a curious item that will forever change his life. When Antar discovers the battered I.D. card of a long-lost acquaintance, he is suddenly drawn into a spellbinding adventure across centuries and around the globe,... |
 | Chromosome Abnormalities and Genetic Counseling (Oxford Monographs on Medical Genetics, No. 46) by R. J. McKinlay Gardner, Grant R. Sutherland Genetic Health Services Victoria and Murdoch Children's Institute, Melbourne, Australia. Discusses genetic counseling and how to help concerned parents make informed decisions. Covers the basics of genetics, parents with chromosomal abnormality, and prenatal diagnosis. Previous edition:... |
 | Three Complete Novels : Contagion, Invasion, Chromosome 6 by Robin Cook From the undisputed master of the medical thriller comes a trio of terrifying tales, filled with Dr. Robin Cook's signature cutting-edge suspense and bold strokes of reality. The consequences of managed health care in an age when even the wariest consumer may be at risk is the catalyst for Contagion, while a sinister cabal involved with unacceptable medical ethics provides the nerve-jangling... |
 | Human Chromosomes by Orlando J. Miller, Eeva Therman The fourth edition of this well-known text provides students, researchers and technicians in the area of medicine, genetics and cell biology with a concise, understandable introduction to the structure and behavior of human chromosomes. It covers both basic and up-to-date material on normal and defective chromosomes. This new edition is particularly strengthened by the complete revision of the... |
 | Chromosome 6 by Robin Cook |
 | First Years of Human Chromosomes: The Beginnings of Human Cytogenetics by Peter S. Harper 2006 marked the 50th anniversary of the discovery of the human chromosome number, establishing human cytogenetics as a scientific discipline and setting the basis for modern medical genetics. First Years of Human Chromosomes draws together the ground-breaking work of the main researchers in the key period 1955 to 1960. The book is based on interviews with these researchers and... |
 | Chromosome 8 by Peter Holt When his lung-damaged daughter, Katya, lies at Death's door, Dr. Gastro Nister goes to extremes to save her, awakening a set of ancient genes left over from primeval times. Not only does Katya survive, but now she has astonishing new inhuman... |
 | Atlas of Human Chromosome Heteromorphisms Clinical cytogenetics is a rapidly changing field. Today's tests are pressed into application almost before the overworked clinician or laboratory director may be aware they are available. Distinction between a normal variant and a clinically significant mutation is a crucial part of any test. Although chromosome banding techniques have been in practical use for more than 30 years, ... |
| Chromosome Anomalies and Prenatal Development: An Atlas (Oxford Monographs on Medical Genetics) by Dorothy Warburton, Julianne Byrne, Nina Canki The lucid color illustrations and succinct text of this atlas provide a unique source of information on abnormal human development. Derived from a long-term collaborative study at Columbia University involving the pathological examination and classification of spontaneous abortion specimens, the volume summarizes years of experience in studying the morphological spectrum characteristic of the... |
| © 2009 BrightSurf.com |